The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland.

To access publisher's full text version of this article click on the hyperlink below Vaccinations with the 10-valent pneumococcal conjugated vaccine (PHiD-CV) started in Iceland in 2011. Protein D (PD) from H. influenzae, which is coded for by the hpd gene, is used as a conjugate in the vaccine...

Full description

Bibliographic Details
Published in:Journal of Clinical Microbiology
Main Authors: Sveinsdóttir, Hildigunnur, Björnsdóttir, Jana Birta, Erlendsdóttir, Helga, Hjálmarsdóttir, Martha Á, Hrafnkelsson, Birgir, Haraldsson, Ásgeir, Kristinsson, Karl G, Haraldsson, Gunnsteinn
Other Authors: 1 University of Iceland, Faculty of Medicine, Reykjavík, Iceland. 2 Department of Clinical Microbiology, Landspitali University Hospital, Reykjavík, Iceland. 3 BioMedical Centre, University of Iceland, Reykjavík, Iceland. 4 Department of Mathematics, University of Iceland, Reykjavík, Iceland. 5 Children's Hospital Iceland, Reykjavík, Iceland. 6 University of Iceland, Faculty of Medicine, Reykjavík, Iceland gah@hi.is.
Format: Article in Journal/Newspaper
Language:English
Published: American Society for Microbiology 2019
Subjects:
Haemophilus influenzae
Iceland
carriage
epidemiology
otitis media
protein D
vaccines
Bakteríusjúkdómar
Inflúensa
Eyrnabólga
Bólusetningar
Haemophilus Infections
Vaccination
Online Access:http://hdl.handle.net/2336/621032
https://doi.org/10.1128/JCM.00116-19
Description
Summary:To access publisher's full text version of this article click on the hyperlink below Vaccinations with the 10-valent pneumococcal conjugated vaccine (PHiD-CV) started in Iceland in 2011. Protein D (PD) from H. influenzae, which is coded for by the hpd gene, is used as a conjugate in the vaccine and may provide protection against PD-positive H. influenzae We aimed to evaluate the effect of PHiD-CV vaccination on H. influenzae in children, both in carriage and in acute otitis media (AOM). H. influenzae was isolated from nasopharyngeal swabs collected from healthy children attending 15 day care centers in 2009 and from 2012 to 2017 and from middle ear (ME) samples from children with AOM collected from 2012 to 2017. All isolates were identified using PCR for the hpd and fucK genes. Of the 3,600 samples collected from healthy children, 2,465 were culture positive for H. influenzae (68.5% carriage rate); of these, 151 (6.1%) contained hpd-negative isolates. Of the 2,847 ME samples collected, 889 (31.2%) were culture positive for H. influenzae; of these, 71 (8.0%) were hpd negative. Despite the same practice throughout the study, the annual number of ME samples reduced from 660 in 2012 to 330 in 2017. The proportions of hpd-negative isolates in unvaccinated versus vaccinated children were 5.6% and 7.0%, respectively, in healthy carriers, and 5.4% and 7.8%, respectively, in ME samples. The proportion of hpd-negative isolates increased with time in ME samples but not in healthy carriers. The number of ME samples from children with AOM decreased. The PHiD-CV had no effect on the proportion of the hpd gene in H. influenzae from carriage, but there was an increase in hpd-negative H. influenzae in otitis media. The proportions of hpd-negative isolates remained similar in vaccinated and unvaccinated children. Icelandic Centre for Research Landspitali University Hospital Research Fund GlaxoSmithKline Biologicals SA

Similar Items